References
- Doran, M.F., et al., Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis & Rheumatism, 2002. 46(3): p. 625–631.
- Goemaere, S., et al., Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. The Journal of rheumatology, 1990. 17(12): p. 1620–1622.
- d’Elia, H.F., et al., Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Annals of the rheumatic diseases, 2003. 62(7): p. 617–623.
- Anderson, G.L., et al., Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. 2004.
- Investigators, W.G.f.t.W.s.H.I., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Jama, 2002. 288(3): p. 321–333.
- D’Elia, H.F., et al., Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. The Journal of rheumatology, 2003. 30(7): p. 1456–1463.
- Jochems, C., et al., Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 2007. 56(10): p. 3261–3270.
- Lafage-Proust, M.H., B. Boudignon, and T. Thomas, Glucocorticoid-induced osteoporosis: pathophysiological data and recent treatments. Joint Bone Spine, 2003. 70(2): p. 109–118.
- Straub, R.H., The complex role of estrogens in inflammation. Endocrine reviews, 2007. 28(5): p. 521–574.
- Deroo, B.J. and K.S. Korach, Estrogen receptors and human disease. The Journal of clinical investigation, 2006. 116(3): p. 561–570.
- Fabian, C.J. and B.F. Kimler, Selective estrogen-receptor modulators for primary prevention of breast cancer. Journal of Clinical Oncology, 2005. 23(8): p. 1644–1655.
- Temin, S., American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Gynecologic oncology, 2009. 115(1): p. 132–134.
- Stefanick, M.L., Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. The American journal of medicine, 2005. 118(12): p. 64–73.
- Jochems, C., et al., Long-term anti-arthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis. Clinical & Experimental Immunology, 2008. 152(3): p. 593–597.
- Green, S. and J. Higgins, Cochrane handbook for systematic reviews of interventions. 2005, Version.
- Higgins, J., Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org, 2011.
- Lee, W., et al., SAT0497 Effect of Raloxifene on Osteoporosis and Disease Activity in Postmenopausal Female with Rheumatic Diseases. Annals of the Rheumatic Diseases, 2014. 73(Suppl 2): p. 772–772.
- Mok, C.C., et al., Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Annals of the rheumatic diseases, 2011. 70(5): p. 778–784.
- Stoica, S. and G. Zugravu, THU0402 Effects of Raloxifene for Prevention of Bone Loss in Rheumatoid Arthritis Women Receiving Long-Term Glucocorticoids. Annals of the Rheumatic Diseases, 2013. 72(Suppl 3): p. A301–A301.
- Mokuda, S., et al., Post-menopausal women with rheumatoid arthritis who are treated with raloxifene or alendronate or glucocorticoids have lower serum undercarboxylated osteocalcin levels. Journal of endocrinological investigation, 2012. 35(7): p. 661–664.
- Guiducci, S., et al., Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis. Arthritis research & therapy, 2005. 7(6): p. R1244.
- Woolf, A.D., An update on glucocorticoid-induced osteoporosis. Current opinion in rheumatology, 2007. 19(4): p. 370–375.
- Angeli, A., et al., High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone, 2006. 39(2): p. 253–259.
- Van Staa, T., et al., Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology, 2000. 39(12): p. 1383–1389.
- De Vries, F., et al., Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case–control study. Journal of internal medicine, 2007. 261(2): p. 170–177.
- Ozmen, B., et al., Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Eur Cytokine Netw, 2007. 18(3): p. 148–153.
- Ettinger, B., et al., Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Jama, 1999. 282(7): p. 637–645.
- Adomaityte, J., M. Farooq, and R. Qayyum, Effect of raloxifene therapy on venous thromboembolism in postmenopausal women: a meta-analysis. Thrombosis and haemostasis, 2008. 99(02): p. 338–342.
- Islander, U., et al., Combined treatment with dexamethasone and raloxifene totally abrogates osteoporosis and joint destruction in experimental postmenopausal arthritis. Arthritis research & therapy, 2011. 13(3): p. R96.
- Taranta, A., et al., The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone, 2002. 30(2): p. 368–376.
- Delmas, P.D., et al., Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New England Journal of Medicine, 1997. 337(23): p. 1641–1647.
- Jochems, C., et al., Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation. Arthritis research & therapy, 2005. 7(4): p. R837.
- Holmdahl, R., L. Jansson, and M. Andersson, Female sex hormones suppress development of collagen-induced arthritis in mice. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 1986. 29(12): p. 1501–1509.
- Yamasaki, D., et al., Effects of ovariectomy and estrogen replacement therapy on arthritis and bone mineral density in rats with collagen-induced arthritis. Bone, 2001. 28(6): p. 634–640.
- Miller, P. and R. Derman, What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Osteoporosis international, 2010. 21(11): p. 1793–1802.
- Miller, P.D., et al., Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. Journal of bone and mineral research, 2008. 23(4): p. 525–535.
- Silverman, S.L., et al., Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. Journal of bone and mineral research, 2008. 23(12): p. 1923–1934.
- Moxley, G., et al., Sexual dimorphism in innate immunity. Arthritis & Rheumatism, 2002. 46(1): p. 250–258.
- Erlandsson, M., et al., Oestrogen receptor specificity in oestradiol-mediated effects on B lymphopoiesis and immunoglobulin production in male mice. Immunology, 2003. 108(3): p. 346–351.
- Messalli, E.M., et al., Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. Maturitas, 2007. 56(1): p. 38–44.
- Cutolo, M., et al., Sex hormones and rheumatoid arthritis. Autoimmunity reviews, 2002. 1(5): p. 284–289.
- Cutolo, M., et al., The role of androgens in rheumatic diseases. The Israel Medical Association journal: IMAJ, 2001. 3(10): p. 743.
- Cutolo, M., et al., Androgen and estrogen receptors are present in primary cultures of human synovial macrophages. The Journal of Clinical Endocrinology & Metabolism, 1996. 81(2): p. 820–827.
- Ushiyama, T., et al., Association of oestrogen receptor gene polymorphisms with age at onset of rheumatoid arthritis. Annals of the rheumatic diseases, 1999. 58(1): p. 7–10.
- Cutolo, M., et al., Androgens and estrogens modulate the immune and inflammatory responses in rheumatoid arthritis. Annals of the New York Academy of Sciences, 2002. 966(1): p. 131–142.
- Cutolo, M., et al., Hypothalamic-pituitary-adrenocortical and gonadal functions in rheumatoid arthritis. Annals of the New York Academy of Sciences, 2003. 992(1): p. 107–117.
- Walsh, B.W., et al., Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. Jama, 1998. 279(18): p. 1445–1451.
- Khalkhali-Ellis, Z., et al., Estrogen and progesterone regulation of human fibroblast-like synoviocyte function in vitro: implications in rheumatoid arthritis. The Journal of rheumatology, 2000. 27(7): p. 1622–1631.
- Fuleihan, G.E.-H., Tissue-specific estrogens—the promise for the future. 1997, Mass Medical Soc.
- Levenson, A.S., et al., Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells. Cancer letters, 1998. 125(1–2): p. 215–220.
- Huber, C., et al., Selective estrogen receptor modulator inhibits osteocyte apoptosis during abrupt estrogen withdrawal: implications for bone quality maintenance. Calcified tissue international, 2007. 81(2): p. 139–144.
- Islander, U., et al., Estrogens in rheumatoid arthritis; the immune system and bone. Molecular and cellular endocrinology, 2011. 335(1): p. 14–29.
- Phillips, K., A. Aliprantis, and J. Coblyn, Strategies for the prevention and treatment of osteoporosis in patients with rheumatoid arthritis. Drugs & aging, 2006. 23(10): p. 773–779.
- Foster, S.A., et al., Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates. BMC women's health, 2008. 8(1): p. 24.
- Kung, A.W., et al., Efficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian women. The Journal of Clinical Endocrinology & Metabolism, 2003. 88(7): p. 3130–3136.